BBO-10203 — Topline data
H2 2026
Updated clinical data are expected in the second half of 2026 and internal combination studies are anticipated to open in 2026.Source filing
BBOT biotech catalysts & pipeline
BRIDGEBIO ONCOLOGY THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
BBO-8520 — Topline data
H2 2026
Updated clinical data from the combination trial with pembrolizumab are expected in the second half of 2026.Source filing